US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Oncology Therapeutics, Inc

3.89

-0.0500-1.27%

Post-market: 3.950.0600+1.54%19:30 EDT

Volume:486.00K

Turnover:1.93M

Market Cap:311.16M

PE:-1.71

High:4.05

Open:3.97

Low:3.88

Close:3.94

52wk High:14.87

52wk Low:3.79

Shares:79.99M

Float Shares:35.75M

Volume Ratio:0.67

T/O Rate:1.36%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2730

EPS(LYR):-4.3039

ROE:-81.92%

ROA:-47.10%

PB:0.96

PE(LYR):-0.90

Loading ...

Overview Company News Filings

BridgeBio Oncology Q2 EPS $(705.20) Misses $(0.57) Estimate

Benzinga Earnings

BridgeBio Oncology Net Loss Widens 98,94% to USD 56,5 Juta in Q2 FY26

Bbot Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

THOMSON REUTERS

Press Release: BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

BridgeBio Oncology Therapeutics Inc Expected to Post a Loss of 57 Cents a Share - Earnings Preview

Bridgebio Oncology Therapeutics Inc : JP Morgan Initiates Coverage with Overweight Rating; Target Price $27

THOMSON REUTERS

Analyst Initiates Buy on BridgeBio Oncology, Sees Significant Upside With $27 Price Target Amid Promising KRAS and PI3Kα Precision Oncology Pipeline

BridgeBio Oncology Therapeutics shareholders elect Lebowitz, McCormick to board

Morgan Stanley Sticks to Their Buy Rating for BridgeBio Oncology Therapeutics (BBOT)

BridgeBio Oncology’s New ERP Rollout Poses Significant Operational and Reporting Risks

Piper Sandler Sticks to Their Buy Rating for BridgeBio Oncology Therapeutics (BBOT)

BridgeBio Oncology Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Bbot Reports First Quarter 2026 Financial Results And Update On Corporate Progress

BridgeBio Oncology Q1 EPS $(526.11) Down From (54.230) YoY,

Benzinga Earnings

BridgeBio Oncology net loss widens to $42.11 million in Q1 FY26

BridgeBio Oncology Therapeutics Inc: Cash Runway Expected to Fund Operations Into 2028

THOMSON REUTERS

Bbot Reports First Quarter 2026 Financial Results and Update on Corporate Progress

THOMSON REUTERS

Press Release: BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress

BridgeBio Oncology awards employee stock options for 32,675 shares at $7.66

BridgeBio Oncology Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/BBOT/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BBOT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBOT\",,,,,undefined,":{"symbol":"BBOT","market":"US","secType":"STK","nameCN":"BridgeBio Oncology Therapeutics, Inc","latestPrice":3.89,"timestamp":1790971200000,"preClose":3.94,"halted":0,"volume":486002,"hourTrading":{"tag":"盘后","latestPrice":3.95,"preClose":3.89,"latestTime":"19:30 EDT","volume":21026,"amount":81806.26,"timestamp":1790983803303,"change":0.06,"changeRate":0.015424,"amplitude":0.015424},"delay":0,"changeRate":-0.012690355329949193,"floatShares":35752400,"shares":79988687,"eps":-2.273,"marketStatus":"Market Closed","change":-0.05,"latestTime":"10-02 16:00:00 EDT","open":3.97,"high":4.045,"low":3.88,"amount":1929863.7379934,"amplitude":0.041878,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.273,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"listingDate":1707454800000,"exchange":"NASDAQ","adjPreClose":3.94,"preHourTrading":{"tag":"盘前","latestPrice":3.94,"preClose":3.94,"latestTime":"08:46 EDT","volume":129,"amount":508.26,"timestamp":1790945213669,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":3.95,"preClose":3.89,"latestTime":"19:30 EDT","volume":21026,"amount":81806.26,"timestamp":1790983803303,"change":0.06,"changeRate":0.015424,"amplitude":0.015424},"volumeRatio":0.6680307635426124},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBOT\",,,,,undefined,":{"symbol":"BBOT","floatShares":35752400,"roa":"-47.10%","roe":"-81.92%","lyrEps":-4.3039,"volumeRatio":0.6680307635426124,"shares":79988687,"dividePrice":0,"high":4.045,"amplitude":0.041878,"preClose":3.94,"low":3.88,"week52Low":3.79,"pbRate":"0.96","week52High":14.87,"institutionHeld":0,"latestPrice":3.89,"eps":-2.273,"divideRate":0,"volume":486002,"delay":0,"ttmEps":-2.273,"open":3.97,"prevYearClose":12.52,"prevWeekClose":3.95,"prevMonthClose":4.1,"prevQuarterClose":4.1,"fiveDayClose":3.95,"twentyDayClose":8.9,"sixtyDayClose":9.09},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBOT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"BBOT","fiscalQuarterEnding":"2026/06","expectedEps":-0.55,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2026-05-12","symbol":"BBOT","fiscalQuarterEnding":"2026/03","expectedEps":-0.51,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.53},{"market":"US","date":"2026-03-05","symbol":"BBOT","fiscalQuarterEnding":"2025/12","expectedEps":-0.67,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2025-11-12","symbol":"BBOT","fiscalQuarterEnding":"2025/09","expectedEps":-0.41,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-1.03},{"market":"US","date":"2025-08-01","symbol":"BBOT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754020800000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBOT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBOT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3636,"buy":0.6364,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6364,"analysts":11,"updateTime":1783569600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BBOT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BBOT","date":"2026-10-02","current":-1.711395,"percent":0.992883,"low":-11.944957,"twenty":-9.524974,"median":-6.024374,"eighty":-4.218087,"high":-1.677323,"avg":-6.736214,"sd":2.72776,"marketCap":315886611},"quantilePoints":[{"date":"2025-08-22","current":-9.544109,"twenty":-10.820609,"median":-9.81087,"eighty":-9.532253,"marketCap":835109579},{"date":"2025-08-29","current":-9.336629,"twenty":-9.787158,"median":-9.514469,"eighty":-9.277349,"marketCap":816955023},{"date":"2025-09-05","current":-9.959071,"twenty":-9.864223,"median":-9.514469,"eighty":-9.247708,"marketCap":871418691},{"date":"2025-09-12","current":-10.047991,"twenty":-10.065775,"median":-9.65773,"eighty":-9.388005,"marketCap":879199215},{"date":"2025-09-19","current":-10.690193,"twenty":-10.20212,"median":-9.78123,"eighty":-9.467045,"marketCap":935391888},{"date":"2025-09-26","current":-11.678196,"twenty":-11.017222,"median":-9.944251,"eighty":-9.487793,"marketCap":1021842155},{"date":"2025-10-03","current":-11.259509,"twenty":-11.190123,"median":-10.077631,"eighty":-9.526325,"marketCap":985207072},{"date":"2025-10-10","current":-11.196152,"twenty":-11.224546,"median":-10.323455,"eighty":-9.563869,"marketCap":979663302},{"date":"2025-10-17","current":-10.3182,"twenty":-11.192532,"median":-10.372506,"eighty":-9.601414,"marketCap":902842494},{"date":"2025-10-24","current":-9.838494,"twenty":-11.156298,"median":-10.223893,"eighty":-9.601414,"marketCap":860868237},{"date":"2025-10-31","current":-10.861263,"twenty":-11.08659,"median":-10.23674,"eighty":-9.656742,"marketCap":950360520},{"date":"2025-11-07","current":-11.087539,"twenty":-11.118284,"median":-10.345353,"eighty":-9.745662,"marketCap":970159697},{"date":"2025-11-14","current":-11.205203,"twenty":-11.201583,"median":-10.472068,"eighty":-9.804136,"marketCap":980455269},{"date":"2025-11-21","current":-8.47671,"twenty":-11.192532,"median":-10.345353,"eighty":-9.572151,"marketCap":974262207},{"date":"2025-11-28","current":-8.567184,"twenty":-11.17443,"median":-10.251046,"eighty":-9.478901,"marketCap":984660736},{"date":"2025-12-05","current":-8.0313,"twenty":-11.121014,"median":-10.182434,"eighty":-9.298176,"marketCap":923069447},{"date":"2025-12-12","current":-8.936039,"twenty":-11.105583,"median":-10.084778,"eighty":-9.061365,"marketCap":1027054741},{"date":"2025-12-19","current":-8.389716,"twenty":-11.080298,"median":-9.97426,"eighty":-8.826299,"marketCap":964263621},{"date":"2025-12-26","current":-8.490629,"twenty":-11.051335,"median":-9.938056,"eighty":-8.720294,"marketCap":975861981},{"date":"2026-01-02","current":-8.713334,"twenty":-11.00789,"median":-9.919954,"eighty":-8.650698,"marketCap":1001458361},{"date":"2026-01-09","current":-9.256178,"twenty":-10.960825,"median":-9.809862,"eighty":-8.597806,"marketCap":1063849537},{"date":"2026-01-16","current":-8.003462,"twenty":-10.901088,"median":-9.61327,"eighty":-8.567184,"marketCap":919869900},{"date":"2026-01-23","current":-7.829474,"twenty":-10.885701,"median":-9.557912,"eighty":-8.530995,"marketCap":899872728},{"date":"2026-01-30","current":-8.699415,"twenty":-10.880305,"median":-9.521034,"eighty":-8.553265,"marketCap":999858587},{"date":"2026-02-06","current":-7.063925,"twenty":-10.867923,"median":-9.470009,"eighty":-8.485061,"marketCap":811885173},{"date":"2026-02-13","current":-7.947786,"twenty":-10.83411,"median":-9.398729,"eighty":-8.38554,"marketCap":913470805},{"date":"2026-02-20","current":-7.043047,"twenty":-10.812388,"median":-9.272371,"eighty":-8.35979,"marketCap":809485512},{"date":"2026-02-27","current":-7.13352,"twenty":-10.763512,"median":-9.179623,"eighty":-8.144045,"marketCap":819884041},{"date":"2026-03-06","current":-6.882977,"twenty":-10.695084,"median":-9.036987,"eighty":-8.006246,"marketCap":791088114},{"date":"2026-03-13","current":-5.451193,"twenty":-10.678337,"median":-8.936039,"eighty":-7.945698,"marketCap":730699673},{"date":"2026-03-20","current":-5.403428,"twenty":-10.588779,"median":-8.821207,"eighty":-7.854528,"marketCap":724297048},{"date":"2026-03-27","current":-5.510899,"twenty":-10.477499,"median":-8.762051,"eighty":-7.489849,"marketCap":738702956},{"date":"2026-04-02","current":-5.391486,"twenty":-10.453966,"median":-8.733947,"eighty":-7.421645,"marketCap":722696391},{"date":"2026-04-10","current":-5.287,"twenty":-10.379747,"median":-8.713334,"eighty":-7.088979,"marketCap":708690647},{"date":"2026-04-17","current":-5.504928,"twenty":-10.361645,"median":-8.657658,"eighty":-7.020776,"marketCap":737902628},{"date":"2026-04-24","current":-5.355662,"twenty":-10.30763,"median":-8.605462,"eighty":-6.799463,"marketCap":717894422},{"date":"2026-05-01","current":-5.021307,"twenty":-10.25963,"median":-8.567184,"eighty":-5.98855,"marketCap":673076041},{"date":"2026-05-08","current":-4.692922,"twenty":-10.225879,"median":-8.553265,"eighty":-5.587323,"marketCap":629057988},{"date":"2026-05-15","current":-4.419866,"twenty":-10.182434,"median":-8.490629,"eighty":-5.506122,"marketCap":681079323},{"date":"2026-05-22","current":-4.73149,"twenty":-10.167401,"median":-8.47671,"eighty":-5.429101,"marketCap":729099017},{"date":"2026-05-29","current":-4.595521,"twenty":-10.107271,"median":-8.403635,"eighty":-5.355662,"marketCap":708146799},{"date":"2026-06-05","current":-4.278409,"twenty":-10.091924,"median":-8.379277,"eighty":-5.319839,"marketCap":659281465},{"date":"2026-06-12","current":-3.878121,"twenty":-10.077631,"median":-8.309681,"eighty":-5.287,"marketCap":597598995},{"date":"2026-06-18","current":-3.992489,"twenty":-10.053919,"median":-8.201809,"eighty":-5.246997,"marketCap":615222558},{"date":"2026-06-26","current":-3.997687,"twenty":-9.989006,"median":-8.066098,"eighty":-5.177737,"marketCap":616023629},{"date":"2026-07-02","current":-4.054871,"twenty":-9.965147,"median":-8.010422,"eighty":-5.018919,"marketCap":624835411},{"date":"2026-07-10","current":-4.725485,"twenty":-9.946462,"median":-7.965184,"eighty":-4.959212,"marketCap":728173575},{"date":"2026-07-17","current":-4.319998,"twenty":-9.932881,"median":-7.944306,"eighty":-4.729088,"marketCap":665690034},{"date":"2026-07-24","current":-4.533138,"twenty":-9.923745,"median":-7.895589,"eighty":-4.678698,"marketCap":698533946},{"date":"2026-07-31","current":-4.41877,"twenty":-9.900032,"median":-7.829474,"eighty":-4.589283,"marketCap":680910384},{"date":"2026-08-07","current":-4.56433,"twenty":-9.857488,"median":-7.544133,"eighty":-4.574377,"marketCap":703340373},{"date":"2026-08-14","current":-4.060031,"twenty":-9.815588,"median":-7.439739,"eighty":-4.568002,"marketCap":739388569},{"date":"2026-08-21","current":-3.997399,"twenty":-9.757518,"median":-7.182237,"eighty":-4.533138,"marketCap":727982344},{"date":"2026-08-28","current":-4.041423,"twenty":-9.678478,"median":-7.105682,"eighty":-4.446842,"marketCap":735999771},{"date":"2026-09-04","current":-3.918156,"twenty":-9.605366,"median":-7.063925,"eighty":-4.423586,"marketCap":713550976},{"date":"2026-09-11","current":-2.430137,"twenty":-9.58639,"median":-7.015208,"eighty":-4.3855,"marketCap":442561953},{"date":"2026-09-18","current":-2.152784,"twenty":-9.555151,"median":-6.914295,"eighty":-4.330395,"marketCap":392052165},{"date":"2026-09-25","current":-1.756566,"twenty":-9.540807,"median":-6.221405,"eighty":-4.290885,"marketCap":319895325},{"date":"2026-10-02","current":-1.734554,"twenty":-9.524974,"median":-6.024374,"eighty":-4.218087,"marketCap":315886611}],"updateTime":1791033629585},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBOT\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658945387","title":"BridgeBio Oncology Q2 EPS $(705.20) Misses $(0.57) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945387","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945387?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:39","pubTimestamp":1786480750,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(705.20) per share which missed the analyst consensus estimate of $(0.57) by 123619.3 percent. This is a 24.49 percent decrease over losses of $(566.46) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61128346/bridgebio-oncology-q2-eps-705-20-misses-0-57-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BridgeBio Oncology Q2 EPS $(705.20) Misses $(0.57) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658943580","title":"BridgeBio Oncology Net Loss Widens 98,94% to USD 56,5 Juta in Q2 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2658943580","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658943580?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:15","pubTimestamp":1786479339,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology net loss widens 98,94% to USD 56,5 juta in Q2 FY26Bridgebio Oncology Therapeutics membukukan rugi bersih kuartal II 2026 melebar menjadi USD 56,5 juta dari USD 28,4 juta setahun seb","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDLyc3Gz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658489199","title":"Bbot Reports Second Quarter 2026 Financial Results and Update on Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2658489199","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658489199?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:05","pubTimestamp":1786478703,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nTUA65NFJY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BBOT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948041","title":"Press Release: BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948041","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948041?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:05","pubTimestamp":1786478700,"startTime":"0","endTime":"0","summary":"-- Continued to advance monotherapy and combination cohorts for all clinical. -- Initiated dosing of BBO-11818 in combination with cetuximab and after the. end of the quarter, initiated dosing of BBO-11818 in combination with. -- Presented preclinical data at AACR highlighting the potency and activity. of BBO-11818 in KRAS mutant tumor models and the efficacy of BBO-10203 in. combination with tucatinib and trastuzumab in HER2amp models. -- Initiated BBO-8520 plus BBO-10203 combination in patients with G12C. NSCLC.BBO-11818: An orally bioavailable small molecule pan-KRAS inhibitor that targets mutant KRAS in both the ON and OFF states.-- Continued to enroll BBO-11818 monotherapy across multiple dose levels.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BBOT","LU0456854461.SGD","BK4097","PRGS","LU0266512127.USD","BK4213","CRC","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654102850","title":"BridgeBio Oncology Therapeutics Inc Expected to Post a Loss of 57 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2654102850","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654102850?lang=en_us&edition=fundamental","pubTime":"2026-07-28 04:16","pubTimestamp":1785183366,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics Inc <BBOT.OQ> expected to post a loss of57cents a share - Earnings PreviewBridgeBio Oncology Therapeutics IncBBOT.OQBBOT.Ois expected to  report resultson July 29 (esti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nL8N43T1XI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4588","BK4139","BBIO","BK4505","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649199384","title":"Bridgebio Oncology Therapeutics Inc : JP Morgan Initiates Coverage with Overweight Rating; Target Price $27","url":"https://stock-news.laohu8.com/highlight/detail?id=2649199384","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649199384?lang=en_us&edition=fundamental","pubTime":"2026-07-08 19:37","pubTimestamp":1783510640,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nFWN43A0V6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BBOT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649184962","title":"Analyst Initiates Buy on BridgeBio Oncology, Sees Significant Upside With $27 Price Target Amid Promising KRAS and PI3Kα Precision Oncology Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2649184962","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649184962?lang=en_us&edition=fundamental","pubTime":"2026-07-08 17:45","pubTimestamp":1783503930,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics (BBOT) has received a new Buy rating, initiated by J.P. Morgan analyst, . Analyst has given his Buy rating due to a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-initiates-buy-on-bridgebio-oncology-sees-significant-upside-with-27-price-target-amid-promising-kras-and-pi3k-precision-oncology-pipeline-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-initiates-buy-on-bridgebio-oncology-sees-significant-upside-with-27-price-target-amid-promising-kras-and-pi3k-precision-oncology-pipeline-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1363072403.SGD","LU1989772840.SGD","LU0210528500.USD","LU1244550221.USD","BK4585","IE00BKVL7J92.USD","LU0098860793.USD","LU2028103732.USD","LU0320765646.SGD","BK4588","LU1244550494.USD","LU2271345857.HKD","BK4139","LU1732799900.SGD","LU1548497426.USD","IAI","BK4516","LU0528227936.USD","LU1074936037.SGD","LU1244550577.SGD","LU2023251221.USD","BK4504","LU1732800096.USD","LU0314104364.USD","LU1791710582.SGD","LU0912757837.SGD","LU1720051108.HKD","LU0158827948.USD","LU2487616109.SGD","LU2347655156.SGD","LU2089284900.SGD","LU0158827781.USD","LU1162221912.USD","LU0267386448.USD","BBOT","LU0106261372.USD","BK4127","LU2264538146.SGD","LU0971096721.USD","LU0225283273.USD","LU2111349929.HKD","LU1988902786.USD","KBWB","LU0053666078.USD","IE00BZ1G4Q59.USD","LU1668664300.SGD","LU2357305700.SGD","LU2089283258.USD","LU0234570918.USD","LU0390134368.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645077100","title":"BridgeBio Oncology Therapeutics shareholders elect Lebowitz, McCormick to board","url":"https://stock-news.laohu8.com/highlight/detail?id=2645077100","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645077100?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:06","pubTimestamp":1782158791,"startTime":"0","endTime":"0","summary":"Bridgebio Oncology Therapeutics held its annual shareholder meeting on June 16, 2026.Shareholders backed the selection of two directors to serve through the 2029 annual meeting.Shareholders ratified Deloitte & Touche as independent registered public accounting firm for fiscal 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL7nB2Sr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBIO","BBOT","BK4139","BK4585","BK4505","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635087051","title":"Morgan Stanley Sticks to Their Buy Rating for BridgeBio Oncology Therapeutics (BBOT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635087051","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635087051?lang=en_us&edition=fundamental","pubTime":"2026-05-15 21:15","pubTimestamp":1778850928,"startTime":"0","endTime":"0","summary":"In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on BridgeBio Oncology Therapeutics, with a price target of $8.5...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-their-buy-rating-for-bridgebio-oncology-therapeutics-bbot-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-their-buy-rating-for-bridgebio-oncology-therapeutics-bbot-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635608917","title":"BridgeBio Oncology’s New ERP Rollout Poses Significant Operational and Reporting Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2635608917","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635608917?lang=en_us&edition=fundamental","pubTime":"2026-05-14 14:01","pubTimestamp":1778738488,"startTime":"0","endTime":"0","summary":"Bridgebio Oncology Therapeutics, Inc. (BBOT) has disclosed a new risk, in the Technology category. Bridgebio Oncology Therapeutics, Inc. faces exec...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bridgebio-oncologys-new-erp-rollout-poses-significant-operational-and-reporting-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bridgebio-oncologys-new-erp-rollout-poses-significant-operational-and-reporting-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635815547","title":"Piper Sandler Sticks to Their Buy Rating for BridgeBio Oncology Therapeutics (BBOT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635815547","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635815547?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:37","pubTimestamp":1778672251,"startTime":"0","endTime":"0","summary":"In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on BridgeBio Oncology Therapeutics, with a price target of $21.00...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-bridgebio-oncology-therapeutics-bbot-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-bridgebio-oncology-therapeutics-bbot-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635226626","title":"BridgeBio Oncology Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635226626","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635226626?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:30","pubTimestamp":1778625003,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryBridgeBio Oncology Therapeutics Inc BBOT.OQ reported a quarterly adjusted loss of 53 cents per shar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P3BV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","BK4588","BBIO","BBOT","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635257072","title":"Bbot Reports First Quarter 2026 Financial Results And Update On Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2635257072","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635257072?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:08","pubTimestamp":1778623728,"startTime":"0","endTime":"0","summary":"May 12 (Reuters) - BridgeBio Oncology Therapeutics Inc ::*BBOT REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND UPDATE ON CORPORATE PROGRESS*BRIDGEBIO ONCOLOGY THERAPEUTICS INC: CASH RUNWAY EXPECTED T","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nRSD8qKHxJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635225197","title":"BridgeBio Oncology Q1 EPS $(526.11) Down From (54.230) YoY,","url":"https://stock-news.laohu8.com/highlight/detail?id=2635225197","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635225197?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:54","pubTimestamp":1778622867,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(526.11).This is a 870.15 percent decrease over losses of $(54.23) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52510501/bridgebio-oncology-q1-eps-526-11-down-from-54-230-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QDTE","ONEQ","QQQA","QQQ","QLD","JEPQ","QQQM","QQQY","QYLG",".IXIC","NVIW.SI","BBOT","TECS","QID","MNQmain","NQmain","QQQE","GPIQ","IYW","FTEC","TQQQ","NDX","TQQY","SQQQ","BK4139","QQQJ","PSQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635223806","title":"BridgeBio Oncology net loss widens to $42.11 million in Q1 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2635223806","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635223806?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:03","pubTimestamp":1778619833,"startTime":"0","endTime":"0","summary":"Bridgebio Oncology Therapeutics posted a net loss of USD 42.1 million, widening from USD 22.1 million a year earlier.R&D expense more than doubled to USD 39.8 million, while G&A expense climbed to USD 6.4 million as standalone operations ramped following de-SPAC.Cash, cash equivalents, and marketable securities totaled USD 388.9 million, with runway expected to fund operations into 2028.Pipeline update flagged a 65% objective response rate for BBO-8520 monotherapy in KRASG12C NSCLC, a partial response with 56% tumor reduction for BBO-11818 in pancreatic cancer, and full target engagement without hyperglycemia for BBO-10203.Updated clinical data across all three programs are expected in second half of 2026, with internal combination studies advancing during 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL8mJkK2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4112","SG9999014039.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014005.SGD","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","BBOT","IE00BN0W2T93.GBP","SG9999014013.SGD","NDAQ","BK4585","LU2095319765.USD","BK4588","BK4139","IE00BN0W2W23.USD","LU0314104364.USD","IE00BN0W2V16.EUR","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635047228","title":"BridgeBio Oncology Therapeutics Inc: Cash Runway Expected to Fund Operations Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2635047228","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635047228?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:03","pubTimestamp":1778619811,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA9SLMNC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635022804","title":"Bbot Reports First Quarter 2026 Financial Results and Update on Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2635022804","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635022804?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:03","pubTimestamp":1778619811,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA9SLMNC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BBOT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635223869","title":"Press Release: BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2635223869","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635223869?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:03","pubTimestamp":1778619780,"startTime":"0","endTime":"0","summary":"-- Announced encouraging preliminary safety and efficacy data across all. -- Announced publication in Cancer Discovery highlighting preclinical data. demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitor. -- Clinical readouts expected in the second half of 2026 across all three. -- Cash runway expected to fund operations into 2028. SOUTH SAN FRANCISCO, Calif., May 12, 2026  -- BridgeBio Oncology Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the first quarter ended March 31, 2026, and provided a business update, including highlights of pipeline progress.BBOT's portfolio of late-stage RAS-pathway inhibitors is designed to enable direct dual inhibition of KRAS in both its ON and OFF states, pan-KRAS coverage across major KRAS mutations, and disruption of RAS-driven PI3K<ALPHA> activation. Together, these assets uniquely position BBOT to achieve safe, concurrent, high-level suppressi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BD6J9T35.USD","BK4097","IE00BZ199S13.USD","BK4512","LU2357305700.SGD","LU1720051017.SGD","BK4141","ON","LU1720051108.HKD","LU0266512127.USD","BK4605","IE00BFMHRM44.USD","LU1978683503.SGD","BK4195","LU0124384867.USD","LU1854104046.USD","LU1861214812.USD","LU0724618433.USD","LU1861219969.SGD","BBOT","LU0456854461.SGD","LU2298322129.HKD","BK4585","LU1861215975.USD","BK4213","LU1861220033.SGD","PRGS","BK4588","PR","ORR","LU1548497426.USD","BK4139","PFS","LU0348723411.USD","LU1854103824.USD","BK4211","CRC","LU2360107325.USD","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635924796","title":"BridgeBio Oncology awards employee stock options for 32,675 shares at $7.66","url":"https://stock-news.laohu8.com/highlight/detail?id=2635924796","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635924796?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:08","pubTimestamp":1778616536,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics awarded inducement equity compensation on May 10, 2026 to one employee hired in March 2026.Grant comprised non-qualified stock options covering 32,675 shares, struck at USD 7.66 per share.Vesting set at 25% on first anniversary of start date, remaining portion in 36 equal monthly installments, contingent on continued service.Awards issued under company’s 2025 Inducement Plan, adopted in October 2025, outside stockholder-approved equity incentive plans.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL2hzXdL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","SG9999014039.USD","BK4112","IE00BKPKM429.USD","SG9999014021.USD","BBIO","LU2210150020.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","BBOT","BK4505","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","BK4139","LU0314104364.USD","BK4585","IE00BN0W2T93.GBP","NDAQ","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4588","LU2210149790.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635924782","title":"BridgeBio Oncology Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635924782","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635924782?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616303,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA2RCLW5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BBOT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":65,"code":"91000000","status":"200"}]}}